Q4 2024 Delivra Health Brands Inc Earnings Call Transcript
Key Points
- Delivra Health Brands Inc (DHBUF) achieved a positive EBITDA for the second consecutive year, reaching approximately $900,000, a significant improvement from a negative $9 million four years ago.
- The company reported a 26% increase in revenue for fiscal 2024, with net sales reaching $12.4 million, up by $2.6 million from the previous year.
- Gross margins expanded from 49% to 52%, demonstrating improved operational efficiency and cost optimization.
- The company successfully eliminated its cash burn, securing financial health and creating a sustainable model for long-term growth.
- Delivra Health Brands Inc (DHBUF) is poised for future growth with plans to expand geographically and invest in innovation and product development.
- Despite improvements, the company still faces concentration risks with a few large customers, which could impact stability if any major customer relationship changes.
- The company took provisions on inventory write-downs of $246,000, indicating challenges with aging SKUs.
- While EBITDA improved, the company increased its spending on marketing and selling initiatives by roughly $1 million, which could impact short-term profitability.
- The company’s growth strategy involves expanding into new geographies, which may present challenges and risks associated with entering new markets.
- There is a reliance on strategic partnerships and distribution networks for scaling in new markets, which could pose risks if these partnerships do not materialize as expected.
Good morning and welcome to the Delivra Health Brands Inc., year-end 2024 results conference call. As a reminder, all participants are in listen-only mode and the conference is being recorded.
Presenting on today's call will be Gord Davey, President and CEO; and Jack Tasse, CFO. (Operator Instructions)
The information communicated by Delivra Health Brands Inc. and company is intended solely for discussion purposes and are not intended as and do not constitute an offer to sell or solicitation of an offer to buy any security and should not be relied upon by you in evaluating the merits of investing in any securities. The company believes the information communicated in this overview to be reliable but makes no warranty or representation, whether expressed or implied, and assumes no legal liability for the accuracy, completeness, and usefulness of any information disclosed.
Any estimates, investment strategies, and views expressed during this conference call are based upon current market conditions and/or data and information provided by an affiliated third party and are subject
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
